Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atovaquone/Azithromycin vs. TMP/SMX for infection prevention in children with HIV
NCT00000811Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of atovaquone and azithromycin in bacterial infection and Pneumocystis pneumonia (PCP) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Rate of serious bacterial infection-related events at 3 years. Status: completed.
02
Drugs
atovaquoneazithromycin
03
Conditions
bacterial infectionPneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on NCT00000811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000811.